Next-Generation Proteomics of Brain Extracellular Vesicles in Schizophrenia Provide New Clues on the Altered Molecular Connectome.
brain antibodies
extracellular vesicles
immunoglobulins
molecular exchange
neuroinflammation
psychiatry
psychotic spectrum
systems biology
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
08 Jan 2024
08 Jan 2024
Historique:
received:
20
12
2023
revised:
30
12
2023
accepted:
05
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Extracellular vesicles (EVs) are tiny membranous structures that mediate intercellular communication. The role(s) of these vesicles have been widely investigated in the context of neurological diseases; however, their potential implications in the neuropathology subjacent to human psychiatric disorders remain mostly unknown. Here, by using next-generation discovery-driven proteomics, we investigate the potential role(s) of brain EVs (bEVs) in schizophrenia (SZ) by analyzing these vesicles from the three post-mortem anatomical brain regions: the prefrontal cortex (PFC), hippocampus (HC), and caudate (CAU). The results obtained indicate that bEVs from SZ-affected brains contain region-specific proteins that are associated with abnormal GABAergic and glutamatergic transmission. Similarly, these vesicles from the analyzed regions were implicated in synaptic decay, abnormal brain immunity, neuron structural imbalances, and impaired cell homeostasis. Our findings also provide evidence, for the first time, that networks of molecular exchange (involving the PFC, HC, and CAU) are potentially active and mediated by EVs in non-diseased brains. Additionally, these bEV-mediated networks seem to have become partially reversed and largely disrupted in the brains of subjects affected by SZ. Taken as a whole, these results open the door to the uncovering of new biological markers and therapeutic targets, based on the compositions of bEVs, for the benefit of patients affected by SZ and related psychotic disorders.
Identifiants
pubmed: 38255234
pii: biomedicines12010129
doi: 10.3390/biomedicines12010129
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI22/00443
Organisme : Agencia Estatal de Investigación
ID : PID2020-114885RB-C21
Organisme : Ministerio de Ciencia e Innovación
ID : PRTR-C17.I1
Organisme : Government of Catalonia
ID : EVBRAINTARGET-Y7340-ACPPCCOL007
Organisme : Diputació de Lleida
ID : PIRS22/03
Organisme : Diputació de Lleida
ID : PIRS23/02
Organisme : Agency for Administration of University and Research
ID : AGAUR 21SGR010065
Organisme : Basque Government
ID : IT211/19
Organisme : Basque Government
ID : IT1512/22